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Summary
Objective: To investigate mitogen activated protein (MAP) kinase pathways for their ability to differentially regulate the expression of matrix
metalloprotease (MMP)-1 and -13 in human chondrosarcoma cells using pathway-selective inhibitors.
Design: Human chondrosarcoma cell lines (SW1353 and JJ012) and human articular chondrocytes (HACs) were treated with cytokines
(IL-1b and TNFa) and the expression of MMP-1 and -13 was analyzed. The effects of MAP kinase inhibitors on cytokine-induced expression
of MMP-1 and -13 were evaluated using ELISA and Western blot analyses. The possible involvement of the Runx2 pathway in mediating p38
effects on MMP-13 expression was analyzed using promoterereporter assays, ELISA and immunoprecipitation analyses.
Results: IL-1b andTNFa strongly induced the expression ofMMP-1 and -13 in SW1353 cells andHACs, whereas only TNFawas found to induce
the expression of these twoMMPs in JJ012 cells. Cytokine treatment did not result in a signiﬁcant increase in the activity of MMPs because of the
excessproductionof endogenous tissue inhibitors ofmetalloproteases (TIMPs). Treatmentwith p38 kinase inhibitors (SB203580andSB242235)
strongly inhibited cytokine-induced MMP-13 expression in a dose-dependent fashion while having a somewhat weaker inhibitory effect on
MMP-1 expression. In contrast, inhibitors of extracellular signal-regulated kinase (ERK) and c-JunN-terminal kinase (JNK) pathways did not inhibit
the expression of either MMP. Overexpression of Runx2 robustly stimulated the transcriptional activation of MMP-13 but had no effect on MMP-1
expression. Furthermore, IL-1b induced the phosphorylation of Runx2, and this effect was blocked by a p38 kinase inhibitor. Our data suggest that
Runx2 is likely to be a key downstream mediator of p38 effects in the differential regulation of IL-1b induced MMP-13 expression.
Conclusions: These studies demonstrate the differential inhibition of cytokine-induced MMP-1 and -13 expression by p38 kinase inhibitors in
human chondrosarcoma cells. Our studies also suggest the involvement of Runx2, at least in part, in mediating the effects of p38 on MMP-13
expression.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Type II collagen is a major component of the cartilage extra-
cellular matrix and it provides structure and tensile strength
to the cartilage matrix. Proteolytic degradation of the carti-
lage matrix is a characteristic feature in joint destruction
seen in rheumatoid arthritis (RA) and osteoarthritis (OA).
Members of the matrix metalloprotease (MMP) family play
a key role in the degradation of type II collagen1,2. A sub-
group of MMPs, known as collagenases (MMP-1, -8, -13)
are the most effective enzymes that can initiate cleavage
of native triple helical collagen that can then be acted
upon by other MMPs. Of these, MMP-13 exhibits the highest
activity towards degrading type II collagen3, and the expres-
sion of MMP-13 is induced in disease states such as OA4.
MMP-1 is expressed in a broad range of normal tissue types,
including ﬁbroblasts and macrophages5. Elevated expres-
sion of MMPs in the joints of OA and RA patients coincides
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Received 3 October 2005; revision accepted 31 January 2006.74with increased levels of pro-inﬂammatory cytokines interleu-
kin-1b (IL-1b) and tumor necrosis factor-a (TNFa) that are
produced in the synovial joint. Cytokines produced by chon-
drocytes and synovial cells have been shown to induce
MMP production leading to cartilage destruction2,6,7.
MMP inhibitors with varying degrees of selectivity for the
various MMPs have shown cartilage protective activity in
animal models of OA8,9. However, the development of
MMP inhibitors as anti-osteoarthritic agents has been ham-
pered by side effects (e.g., musculoskeletal syndrome,
MSS) observed in clinical trials10,11. The mechanism of
MSS is not understood. It is presumed that MMP-1 activity
would be required for normal physiological processes like
matrix remodeling, and its inhibition could be one of the
causative factors for the undesirable side effects12. Inhibi-
tors that selectively inhibit the elevated levels of MMP-13
in pathological situations would therefore be desirable.
Most of the efforts towards MMP inhibition have focused
on the development of enzyme activity inhibitors. In this
study, we have focused on mechanisms that are involved
in the regulation of enzyme synthesis. We have performed
studies to better understand the signaling pathways that dif-
ferentially regulate the expression of MMP-1 and -13, in an
effort to identify selective inhibitors of MMP expression.9
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serine/threonine (Ser/Thr) kinases plays a role in mediating
the cytokine-induced expression of MMPs13. The MAPK
family consists of the c-Jun N-terminal kinases (JNKs),
the extracellular signal-regulated kinases (ERKs) and the
p38 kinases. The JNK and p38 kinases are activated in
response to inﬂammatory cytokines like IL-1 and TNF,
osmotic stress and apoptotic signals14, while the ERKs
mediate signaling by cytokines, growth factors and phorbol
esters15,16. In this study, we investigated the effects of p38
inhibitors on the cytokine-stimulated expression of MMP-1
and -13 in human chondrocytic cells. Our results indicate
that p38 kinase inhibitors differentially regulate the expres-
sion of MMP-1 and -13.
Runx2 is a transcription factor that promotes chondrocyte
maturation and osteoblast differentiation17e23. It activates
transcription by binding to DNA sequence elements
(OSE2) that are found in the promoters of a number of
genes expressed in osteoblasts and chondrocytes that
are targets of Runx2 transactivation17,24. Since the MMP-
13 promoter contains a Runx2 binding element25,26 and
the Runx2 protein has been shown to co-localize with
MMP-13 in osteoarthritic cartilage27, we evaluated the role
of Runx2 in mediating p38 effects on MMP-13 expression.
Overexpression of Runx2 robustly induced MMP-13 tran-
scription while having no effect on MMP-1 expression.
The regulation of MMP-13 but not MMP-1 expression by
Runx2 led us to speculate that Runx2 could mediate, at
least in part, the effect of p38 on the MMP-13 promoter.
We have shown that IL-1b induces the phosphorylation of
Runx2, and this effect is blocked by an inhibitor of p38
kinase, implicating Runx2 as a target of p38 action. Our
data suggest that Runx2 could be one of the downstream
mediators of p38 effects in the differential regulation of
IL-1b-induced MMP-1 and -13 expression.
Materials and methods
CELL CULTURE
The SW1353 human chondrosarcoma cell line was
obtained from ATCC (Bethesda, MD) and was grown in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) (Invitrogen,
Carlsbad, CA, #11965-092) supplementedwith 10% fetal bo-
vine serum (FBS, Invitrogen). The ATCC catalog states that
the SW1353 cell line was initiated by A. Leibovitz at the Scott
and White Clinic, Temple, TX in 1977 from a primary grade II
chondrosarcoma of the right humerus obtained from a 72-
year-old female Caucasian. The human chondrosarcoma
cell line JJ012 was obtained from Dr. Joel Block (Rush Pres-
byterian St. Luke’sMedical Center, Chicago, IL)28,29 andwas
grown in complete medium consisting of 40% DMEM (Invi-
trogen, #11965-092), 40% MEMa (Invitrogen), 10% Ham’s
F-12 (Invitrogen), 10% FBS, 0.036% hydrocortisone (Sigma,
St. Louis,MO), 0.1 units/ml humulinR (Eli Lilly andCompany,
Indianapolis, IN), and 25 mg/ml Vitamin C (Sigma, St. Louis,
MO). With IRB approval, human articular chondrocytes
(HACs) were isolated from the knee joint cartilage of OA pa-
tients undergoing knee replacement surgery (St. Francis
Hospital, Beech Grove, IN). The healthy-looking cartilage
was shavedoff the femoral condyle and tibial plateau,minced
anddigested in 1%protease solution [DMEMwith sodiumpy-
ruvate (Invitrogen, # 11995-065), 1% antibioticeantimycotic
solution (Invitrogen), 1% insulinetransferrineSelenium-X
(ITS, Invitrogen), and 1% protease (Sigma)] for 1 h at 37(C.
The cartilage was then washed with the serum-free media
(DMEM with sodium pyruvate, 1% each of ITS andantibioticeantimycotic solution) and digested overnight at
37(C in 0.1%collagenase solution [DMEMwith sodiumpyru-
vate, 1% antibioticeantimycotic solution, 1% ITS, and 0.1%
collagenase (Worthington, Lakewood, NJ)]. After the diges-
tion, the cells were passed through a 100micron cell strainer,
washed with the serum-free medium and resuspended in the
HAC culture medium (DMEMwith sodium pyruvate, 1% anti-
bioticeantimycotic solution, 1% ITS, and 10% FBS).
RNA PURIFICATION AND cDNA SYNTHESIS
Total RNAs were extracted with Tripure Reagent (Roche,
Indianapolis, IN) according to the manufacturer’s protocol
with modiﬁcation. Brieﬂy, cell culture media were removed
and the cells were lysed on plate with the Tripure Reagent.
Then the lysate was mixed with 0.2 volumes of chloroform
and subjected to centrifugation. The upper phase was
transferred to a new tube and the RNA was precipitated
with equal volume of isopropanol. The RNA pellet was dis-
solved in diethyl pyrocarbonate (DEPC)-treated water, and
was extracted twice with phenol, pH 4.3, to remove any im-
purity. The RNA was then precipitated with two volumes of
ethanol. Any residual DNA was removed by treating the pu-
riﬁed total RNA with DNase using DNA-free kit (Ambion,
Austin, TX) according to the manufacturer’s protocol. Mes-
senger RNA was puriﬁed using the Oligotex kit (Qiagen, Va-
lencia, CA) according to the manufacturer’s protocol. mRNA
(500 ng) was used to synthesize cDNA using the Super-
Script ﬁrst-strand synthesis system for reverse transcrip-
tion-polymerase chain reaction (RT-PCR) (Invitrogen,
Carlsbad, CA) following the manufacturer’s protocol. The
above-synthesized cDNA (2 ml) was analyzed by PCR us-
ing AmpliTaq Gold (Applied Biosystems, Foster City, CA).
REAL-TIME PCR
Real-time PCR was performed with an ABI Prism 7900
Sequence Detection System (Applied Biosystems, Foster
City, CA). All genes were analyzed in triplicate using
Assay-on-Demand (Applied Biosystems) primereprobe
sets under conditions recommended by the manufacturer.
The reaction was performed in a 50 ml mixture containing
1 Taqman Master Mix (Applied Biosystems) and 2 ml of
the above-synthesized cDNA. GAPDH was used as the in-
ternal control. The relative quantities of each gene were de-
termined by the manufacturer’s default DDCt method.
WESTERN BLOT ANALYSIS
SW1353 cells were plated in complete media in 6-well
plates at a density of 2 105 cells/well and allowed to settle
down overnight. Then the cells were washed twice with
phosphate buffered saline (PBS) and replenished with
1 ml of serum-free medium (0.2% lactalbumin hydrolysate
in DMEM), containing IL-1b þ/ different doses of
SB203580. After 24 h of incubation, 450 ml of the superna-
tant was concentrated by passing through a Microcon
YM10 column (Millipore, Bedford, MA). The sample was
separated on a denaturing sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) 4e20% gradi-
ent gel and transferred to a polyvinylidene ﬂuoride (PVDF)
membrane. The membrane was blocked for 1 h in blocking
buffer containing PBS and 5% powdered milk at room tem-
perature. The membrane was then incubated overnight at
4(C in blocking buffer containing either anti-human MMP-1
(Abcam, Cambridgeshire, UK) or MMP-13 polyclonal
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tion, respectively. The membrane was washed three times,
15 min each with wash buffer that contains PBS and 0.2%
Tween-20. It was incubated with the appropriate secondary
antibodies for 2 h at room temperature. The membrane was
washed three times again with the wash buffer and devel-
oped by ECL-Plus (Amersham, Buckinghamshire, UK).
ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
For quantiﬁcation of MMP and tissue inhibitors of metallo-
protease (TIMP) levels in the conditioned media, SW1353
and JJ012 cells were plated in triplicate in 96-well plates
at a density of 4 104 cells/well. For HAC, the cells were
plated at a density of 1 105 cells/well of a 96-well plate,
and allowed to attach for 4 or 5 days and then fresh media
was added. The next day, the culture medium was replaced
with fresh medium (200 ml/well) containing vehicle, IL-1b or
TNFa (R&D Systems, Minneapolis, MN) þ/ SB203580,
SB242235, PD98059, U0126 (all from Calbiochem, San
Diego, CA), SP60012530 or vehicle. After 24 h of incuba-
tion, supernatants were collected and stored at 80(C for
future analysis by ELISA. Human MMP-1, -13, and TIMP-1
ELISA kits were purchased from Amersham Biosciences
(Buckinghamshire, UK). Human TIMP-2 ELISA kits were
from R&D Systems. In general, the experiments were per-
formed at least three times and data from representative ex-
periments are shown.
DNA TRANSFECTION AND REPORTER GENE ASSAYS
Promoter regions containing a 2.6 kb 50-ﬂanking region of
the human MMP-1 gene (2493 to þ71)31 and a 1.6 kb 50-
ﬂanking region of the human MMP-13 gene (1593 to
þ28)32 were cloned by Genome walking PCR (Clontech,
Palo Alto, CA). These promoter regions were cloned up-
stream of the bgal reporter gene in the vector pbgal-Basic
(Clontech) to generate promoterereporter constructs
(MMP-1bgal and MMP-13bgal). Of the promoterereporter
constructs, 1 mg each was transfected into SW1353 cells
using Fugene6 transfection reagent (Roche, Indianapolis,
IN). For transactivation studies, the promoterereporter con-
structs were cotransfected with 1 mg of a Runx2 expression
construct (pEF-Runx2)33 or an empty expression vector
(pEF/myc/cyto) (Invitrogen). bgal activity in cell extracts
was measured 36e48 h after transfection using a lumines-
cent bgal assay kit (Roche, Indianapolis, IN).
Runx2 OVEREXPRESSION TO ASSESS ENDOGENOUS MMP
LEVELS
SW1353 cells were plated in 6-well plates at a density of
1 105 cells/well. On the following day the cells were trans-
fected overnight with 1 mg of the Runx2 expression con-
struct33 or empty vector pEF/myc/cyto (Invitrogen) using
Fugene6 transfection reagent (Roche). The next day, the
media were changed and the cells were incubated in
0.1% serum-containing medium for 24 h. MMP-1 and -13
levels in the conditioned media were measured by ELISA.
IMMUNOPRECIPITATION: Runx2 PHOSPHORYLATION
ANALYSIS
SW1353 cells were plated in 15 cm dishes and on the fol-
lowing day the cells (about 75% conﬂuent) were treated
with IL-1b (0.5 ng/ml) þ/ SB203580 (1 mM) for 3 h. Thecells were then lysed with radioimmunoprecipitation
(RIPA) buffer (1% NP-40, 0.1% SDS, 0.5 mM ethylene di-
amine tetra acetic acid (EDTA), 50 mM TriseHCl, pH 7.5,
supplemented with 2 mM Pefabloc, 10 mM Na3VO4 and
2.5 mM NaF right before use). The Runx2 protein in each
sample was immunoprecipitated with 2 mg of goat anti-
Runx2 antibody (Santa Cruz Biologicals, Santa Cruz, CA),
and Protein G plus/Protein A Agarose (Calbiochem) over-
night at 4(C. After separating the immunoprecipitated sam-
ples on SDS-PAGE and transferring to PVDF membrane,
the phospho-group was detected using an anti-phospho-
Ser/Thr antibody (Cell Signaling, Beverly, MA) followed by
goat anti-rabbit HRP secondary (Jackson Immuno Re-
search, West Grove, PA) and the membrane was developed
using ECL-Plus (Amersham). Densitometric quantitation of
the bands corresponding to the phosho-Runx2 protein
was performed using a Kodak Image System 2000MM.
Results
CYTOKINE INDUCTION OF MMP-1 AND -13 EXPRESSION
IN HUMAN CHONDROSARCOMA CELLS
SW1353 human chondrosarcoma cells were treated with
either IL-1b (10 ng/ml) or TNFa (10 ng/ml) and the expres-
sion of MMP-1 and -13 mRNA and protein were analyzed.
Consistent with previous ﬁndings13, both IL-1b and TNFa re-
sulted in a signiﬁcant upregulation of MMP-1 and -13 mRNA
expression in SW1353 cells and a corresponding increase
in protein levels in the culture medium. Peak induction of
both MMPs was observed at 24 h post-cytokine treatment.
In a doseeresponse analysis, we found that IL-1b at
a dose as low as 0.5 ng/ml was able to induce MMP-13 pro-
tein levels by 23-fold and MMP-1 protein levels by 12-fold,
which are close to the maximal level of response (data not
shown). Furthermore, co-treatment with IL-1b and TNFa re-
sulted in a synergistic increase in MMP-1 and -13 protein
levels in these cells. Treatment of JJ012 human chondrosar-
coma cells with TNFa (but not IL-1b) also resulted in an in-
crease in the levels of MMP-1 and -13 proteins in the culture
medium (data not shown). We did not see any response to
IL-1 in JJ012 cells at any of the time points we have tested,
suggesting a possible lack of some component of the IL-1
signaling pathway in these cells.
Although cytokines dramatically increased MMP-13 ex-
pression, an MMP-13 activity ELISA (Amersham) failed to
show a corresponding increase in MMP-13 activity in the
culture medium in SW1353 cells. Previous studies have
demonstrated the expression of TIMPs in SW1353 cells
that act as endogenous inhibitors of MMP activity34. To
measure the actual level of expression of TIMP-1 and
TIMP-2 in SW1353 cells, we performed ELISAs using cul-
ture supernatants. The levels of TIMP-1 and TIMP-2 are
shown in Table I. TIMPs block MMP proteolytic activity by
interacting with the MMP active site in a 1:1 molar stoichi-
ometry35,36. The molar ratio that we observed between
cytokine activated levels of TIMPs (-1 and -2) and MMPs
Table I
Expression levels of TIMPs and MMPs in SW1353 cells
Molecular
weight
(kDa)
Amount
(ng/ml)
Molar
amount
(mM)
Combined
amount
(mM)
Ratio
(TIMP/
MMP)
TIMP-1 28.5 140.33 4.92 5.57 18:1
TIMP-2 21 13.7 0.65
MMP-1 57 14.8 0.26 0.306
MMP-13 60 2.76 0.046
752 Yong Pei et al.: Differential regulation of MMP-1 and -13 expression by p38 kinase inhibitors(-1 and -13) was 18:1 (Table I). It is likely that the excess
amount of endogenous TIMPs block MMP activity in the cul-
ture supernatant and would render them inactive.
DIFFERENTIAL REGULATION OF CYTOKINE-INDUCED MMP-1
AND -13 EXPRESSION BY p38 KINASE INHIBITORS IN HUMAN
CHONDROCYTIC CELLS
We next evaluated the effects of various concentrations
of p38 kinase inhibitors on cytokine-induced expression ofMMP-1 and -13. Treatment of SW1353 cells with the p38 in-
hibitor SB203580 resulted in a dose-dependent inhibition of
IL-1b induced MMP-13 mRNA levels, with an IC50 of ap-
proximately 10e100 nM. In contrast the inhibitor had no ef-
fect on IL-1b-induced MMP-1 mRNA levels [Fig. 1(a)]. The
differential inhibition of MMP-13 expression, but not MMP-1
expression, by SB203580 was also conﬁrmed at the protein
level using Western blot analysis of conditioned media
[Fig. 1(b)]. To determine if other inhibitors of p38 kinase
would also demonstrate differential inhibition of MMP-1100
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Fig. 1. Differential regulation of cytokine-induced MMP-1 and -13 expression by p38 kinase inhibitors in SW1353 cells. (a) Cells were treated
with 0.5 ng/ml IL-1b in the presence or absence of the p38 inhibitor SB203580 for 24 h in complete medium. mRNAs were puriﬁed, cDNAs
were synthesized and the samples were analyzed by real-time PCR. mRNA levels were quantiﬁed using the DDCt method. GAPDH was used
as an endogenous control. (b) Cells were treated with 0.5 ng/ml IL-1b in the presence of SB203580 for 24 h in serum-free medium supple-
mented with 0.2% lactalbumin hydrolysate. Conditioned media were concentrated and subjected to Western blot analysis to determine
MMP-1 and -13 protein levels. (c) Cells were plated in 96-well plates at a density of 4 104 cells/well and were treated with IL-1b in the pres-
ence or absence of the p38 kinase inhibitors SB203580 or SB242235 for 24 h. Levels of MMP-1 and -13 in the conditioned media were mea-
sured by ELISA. (d) Cells were treated with TNFa þ/ SB203580 or SB242235, and the levels of MMP-1 and -13 in the conditioned media
were measured by ELISA.
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Fig. 2. Differential regulation of TNFa-induced MMP-1 and -13 expression by p38 kinase inhibitors in JJ012 cells. JJ012 cells were plated in
96-well plates at a density of 4 104 cells/well and were treated with TNFa in the presence or absence of the p38 kinase inhibitors SB203580
or SB242235. MMP-1 and -13 protein levels in the conditioned media were measured by ELISA.and -13, we treated the cells with IL-1b in combination with
SB203580 or another p38 inhibitor, SB242235, and per-
formed ELISA assays to determine MMP-1 and -13 levels
in the culture medium. Both inhibitors resulted in a dose-
dependent inhibition of IL-1-induced MMP-13 expression,
while having a somewhat weaker inhibitory effect onMMP-1 expression [Fig. 1(c)]. To determine whether the ob-
served difference in regulation would also be applicable
in the TNFa-induced system, we treated the cells with
TNFa in combination with SB203580 or SB242235 and
measured MMP-1 and -13 levels in the culture medium.
As with the IL-1-induced system, both inhibitors resultedControl
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Fig. 3. Differential regulation of cytokine-induced MMP-1 and -13 expression by SB203580 in HACs. (a, c) Cytokine induction of MMP-1 and
-13 protein levels in HACs. HACs were plated at a density of 1 105 cells/well in a 96-well plate, allowed to attach for 4e5 days and then the
medium was changed. The next day, the culture medium was replaced with medium (200 ml/well) containing IL-1b (1 ng/ml) (a) or TNFa
(10 ng/ml) (c). After 24 h, the levels of MMP-1 and -13 in the conditioned media were measured by ELISA. (b, d) Cells were treated with
IL-1b þ/ a dose range of SB203580 or TNFa þ/ a dose range of SB203580 for 24 h and the MMP-1 and -13 protein levels in the condi-
tioned media were measured by ELISA.
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expression, while having a weaker inhibitory effect on
MMP-1 expression [Fig. 1(d)]. Consistent with this observa-
tion in SW1353 cells, differential inhibition of TNFa-induced
MMP-13 and -1 expression by SB203580 and SB242235
was also observed in JJ012 cells (Fig. 2).
To evaluate whether the differential regulation of MMP-1
and -13 expression by p38 kinase inhibitors would also
occur in HACs, we isolated normal healthy-looking articular
chondrocytes from the knee joints of patients undergoing
joint replacement surgery. Treatment of these cells with
either IL-1b or TNFa resulted in a robust stimulation of
MMP-1 and -13 protein levels in the culture medium
[Fig. 3(a, c)]. Addition of SB203580 resulted in a dose-
dependent inhibition of MMP-13 expression. MMP-1
expression was also inhibited, but there was some separa-
tion in the inhibitory proﬁles on MMP-1 and -13 expression
[Fig. 3(b, d)]. This observation suggests that the pheno-
menon of differential regulation of MMP-1 and -13
expression by p38 kinase inhibitors is applicable to a limited
extent to human chondrocytes. In HAC culture superna-
tants, we also observed high levels of expression of
TIMP-1 (w500 ng/ml) and the levels were not affected by
cytokine treatment.
ERKANDJNK INHIBITORSDONOT INHIBITCYTOKINE-INDUCED
EXPRESSION OF MMP-1 AND -13
Having observed inhibition of MMP-13 expression by p38
kinase inhibitors, we evaluated whether inhibition of other
members of the MAP kinase pathway (ERK and JNK)
was effective in blocking MMP-1 and -13 expression ina differential fashion. We tested the effects of ERK inhibitors
(PD98059 and U0126) on IL-1b-induced MMP expression
in SW1353 cells. Interestingly, neither of the ERK inhibitors
had any effect on MMP-13 or MMP-1 expression up to
a dose of 10 mM [Fig. 4(a, b)]. This result is consistent
with previously reported ﬁndings13. To test the involvement
of the JNK pathway in mediating MMP-1 and -13 expres-
sion, we used SP600125, a selective inhibitor of the JNK
pathway, in cytokine-treated SW1353 cells. SP600125
also did not affect the cytokine-induced expression of
MMP-1 or MMP-13 [Fig. 4(c)].
STIMULATION OF MMP-13 BUT NOT MMP-1 EXPRESSION
BY Runx2
MMP-13 is a known target of Runx2 action25 and the
MMP-13 promoter contains a distinct Runx2 binding ele-
ment (OSE2) that is not seen in the MMP-1 promoter26. In
order to demonstrate the regulation of MMP-13 but not
MMP-1 promoter activity byRunx2, we generated promotere
reporter constructs containing 2.6 kb and 1.6 kb regions of
the MMP-1 and -13 promoters, respectively, that were linked
to the bgal reporter gene in the vector pbgal-Basic. To dem-
onstrate the functionality of the promoters, SW1353 cells
were transfected with the promoterereporter constructs and
bgal activity was measured in cell extracts 36-48 h post-
transfection. Both promoter constructs showed substantial
activity in these cells compared to the promoterless-bgal
vector (pbgal-Basic) suggestive of promoter functionality
in this cell line [Fig. 5(a)]. To test the effects of Runx2 on
promoter activity, we cotransfected the MMP-1 and -13
promoterebgal constructs along with a Runx2 expression-20
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Fig. 4. ERK and JNK inhibitors do not inhibit the cytokine-induced expression of MMP-1 or MMP-13. SW1353 cells were plated in 96-well
plates at a density of 4 104 cells/well. Cells were then treated with IL-1b in the presence or absence of the ERK inhibitors PD98059 (a),
U0126 (b), or the JNK inhibitor SP600125 (c) for 24 h. The levels of MMP-1 and -13 in the conditioned media were measured by ELISA.
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Fig. 5. Selective induction of MMP-13 but not MMP-1 expression by Runx2. (a) SW1353 cells were plated at a density of 1 105 cells/well in
6-well plates. To determine basal levels of expression, 1 mg of the MMP-1 promoterebgal, the MMP-13 promoterebgal, and the pbgal-Basic
constructs were transiently transfected into SW1353 cells and the bgal activity in cell extracts was measured 36e48 h after transfection. (b) To
determine Runx2-inducibility, the promoterereporter constructs were transiently cotransfected along with the Runx2 expression construct
(pEF-Runx2) or the empty vector (pEF/myc/cyto). Each plasmid (1 mg) was used to transfect the cells. bgal activity in cell extracts was mea-
sured 36e48 h after transfection. (c) SW1353 cells were plated in 6-well plates at a density of 1 105 cells/well. On the following day, the cells
were transfected overnight with 1 mg of the Runx2 expression construct or empty vector using Fugene6 transfection reagent (Roche). The next
day, the media were changed and the cells were incubated in 0.1% serum-containing medium for 24 h. MMP-1 and -13 levels in the culture
media were measured by ELISA.construct (pEF-Runx2) or the empty vector
(pEF/myc/cyto). We conﬁrmed by real-time PCR that
Runx2 overexpression did result in a substantial increase
in Runx2 mRNA levels in transfected cells (relative quantity:
w90,000). Measurement of bgal activity in cell extracts indi-
cated a robust transactivation of the MMP-13 promoter by
Runx2. In contrast, Runx2 overexpression had no effect
on the MMP-1 promoter and the promoterless vector
[Fig. 5(b)]. Runx2 overexpression also led to an increase
in endogenous MMP-13 protein levels in the culture super-
natant, while having no discernible effect on MMP-1 protein
levels [Fig. 5(c)]. These results are consistent with a role for
the Runx2 pathway, at least in part, in mediating the regula-
tion of MMP-13 expression by p38 kinase.
We did not perform the promoter studies in the presence
of IL-1, because Mengshol et al.26 have shown that IL-1
does not stimulate transiently transfected MMP-13
promoterereporter constructs. Instead, they reported that
IL-1 actually inhibited MMP-13 promoter activity and
co-transfecting an expression plasmid for Runx2 did not
restore IL-1 induction. This does not corroborate with the
upregulation of endogenous MMP-13 by IL-1. They suggest
that the discrepancy reﬂects the need for chromosomal in-
tegration of the gene to be responsive to IL-1. Considering
these data, we decided to focus instead on analyzing the
phosphorylation status of endogenous Runx2 in response
to IL-1 treatment.IL-1b TREATMENT LEADS TO THE PHOSPHORYLATION
OF Runx2 AND THIS EFFECT IS BLOCKED BY A p38
KINASE INHIBITOR
To further establish the involvement of the Runx2 path-
way in mediating p38 effects on cytokine-induced MMP-
13 expression, we ﬁrst tested whether IL-1b treatment leads
to the phosphorylation of Runx2, and if a p38 inhibitor would
block this effect. SW1353 cells were treated with IL-1b with
and without SB203580 and the amount of phosphorylated
Runx2 protein in the cell extracts was analyzed on a West-
ern blot. As shown in Fig. 6(a), IL-1b treatment did induce
the phosphorylation of Runx2, and this increase in phos-
phorylation was blocked by SB203580. Similar effects
were observed when cells were pretreated with the inhibitor
30 min prior to the addition of IL-1b. Densitometric quantita-
tion of the bands is shown in Fig. 6(b). These data suggest
that Runx2 is a potential downstream target of p38 kinase,
and that the inhibition of MMP-13 expression by p38 kinase
inhibitors could be mediated, at least in part, via the inhibi-
tion of Runx2 phosphorylation.
Discussion
MMPs play a key role in cartilage matrix breakdown seen
in arthritic conditions. The expression of MMP-13, one of
the key proteases involved in type II collagen breakdown,
756 Yong Pei et al.: Differential regulation of MMP-1 and -13 expression by p38 kinase inhibitorsis upregulated in the diseased state. A number of broad-
spectrum MMP active site inhibitors have been developed
for use in treating arthritis, but their use has been limited
by the side effects observed in clinical trials. Inhibition of
MMP-1 is considered to be one of the reasons for the induc-
tion of side effects. In an effort to identify more selective in-
hibitors of MMPs, we have focused on the signaling
pathways that play a role in regulating MMP synthesis in hu-
man chondrocytic cells.
IL-1b and TNFa strongly induced the expression of
MMP-1 and -13 in SW1353 cells, as reported previously13,
whereas only TNFa was found to induce the expression of
MMP-1 and -13 in JJ012 cells. The JJ012 cells may lack
some component of the IL-1 signaling pathway that could
make them unresponsive to IL-1. Previous studies on the
effects of MAP kinase inhibitors on MMP expression in
chondrosarcoma cells relied on Western blotting (which
has sensitivity limitations) and a clear doseeresponse anal-
ysis was not performed13,26. In this study, using a broad
dose range of inhibitors and sensitive assay methodologies
(real-time PCR, and sandwich ELISA assays), we tested
the effects of selective inhibitors of different MAPK path-
ways and have demonstrated that the p38 kinase pathway
differentially regulates cytokine-induced MMP-13 expres-
sion in SW1353 chondrosarcoma cells while sparing
MMP-1 expression. Differential inhibitory effects were also
observed in the chondrosarcoma cell line JJ012 and in
HACs, although the separation in effects on MMP-1 and
-13 was smaller.
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Fig. 6. Inhibition of IL-1b-induced phosphorylation of Runx2 by
SB203580. (a) SW1353 cells were treated with IL-1b (0.5 ng/ml)
in the presence or absence of SB203580 (1 mM) for 3 h. The cells
were then lysed and the Runx2 protein in each sample was immu-
noprecipitated with 2 mg of goat anti-Runx2 antibody. After separat-
ing the immunoprecipitated samples on SDS-PAGEand transferring
to membrane, the phospho-group was detected using an anti-
phospho-Ser/Thr antibody, and themembrane was developed using
the ECL-Plus kit. (b) Quantitation of phosphor-Runx2 levels using
densitometric scanning of the X-ray ﬁlm.In contrast to the preferential inhibition of MMP-13 ex-
pression by p38 inhibitors, ERK and JNK inhibitors did not
affect the expression of either MMP in these cells. However,
based on overexpression of a JNK-interacting protein (JIP),
a cytoplasmic scaffold protein that binds JNK and seques-
ters it in the cytoplasm37,38, Mengshol et al.13 have shown
that the JNK pathway is needed for MMP-13 expression
in SW1353 cells. Nevertheless, in our studies involving
a speciﬁc inhibitor of JNK kinases, we did not see any
effects of the inhibitor on cytokine-induced expression of
MMP-1 or -13 in SW1353 cells. Since the mechanisms
of inhibition are different in these situations (sequestering
of JNK in the cytoplasm by JIP versus inhibition of the
kinase activity of JNK by SP600125), it is conceivable that
the JIP-mediated inhibition of the non-catalytic functions of
JNK is likely responsible for the down-regulation of MMP-
13 expression seen in the previous study. In addition,
SP600125 has been shown to inhibit ﬁbronectin fragment
(Fn-f)-induced MMP-13 expression in C-28I2 immortalized
human chondrocytes39 and in primary HAC monolayers40.
In the latter study, it has been reported that incubation
with IL-1Ra, an antagonist of IL-1 signaling completely
blocked IL-1b-induced increase in MMP-13 expression,
but had a weaker inhibitory effect on Fn-f-induced MMP-
13 expression. This suggests that non-overlapping path-
ways may be involved, at least in part, in mediating IL-1
and Fn-f effects on MMP-13 expression, and that SP600125
may have a stronger inhibitory effect on MMP-13 in the Fn-f
induced system.
Using JNK knockout mice and the selective JNK inhibitor
SP600125, Han et al.30 have shown that JNK activity is re-
quired for MMP-13 expression in ﬁbroblast-like synovio-
cytes and synovium. This could be due to the utilization of
different MAP kinase signaling pathways in ﬁbroblasts vs
chondrocytes in the regulation of MMP expression as sug-
gested by the studies of Mengshol et al.13.
In order to understand the mechanism involved in the dif-
ferential inhibition of MMP-1 and -13 expression by p38
inhibitors, we sought to identify the potential mediators of
p38 kinase action on MMP-13 gene regulation. MMP-13
has been shown to be a direct target of the transcription fac-
tor Runx225,41 that plays a major role in chondrocyte matu-
ration and osteoblast differentiation17e23. Runx2 activates
MMP-13 expression by binding to OSE2 elements in the
MMP-13 promoter25,41. This, combined with the absence
of an OSE2 element in the MMP-1 promoter26 suggested
that Runx2 may play a role in mediating, at least in part,
the effects of p38 on the MMP-13 promoter. Mengshol
et al.26 have also shown that Runx2 is one of the factors
required for optimal stimulation of MMP-13 expression by
IL-1. Using immunoprecipitation analysis with phospho-
speciﬁc antibodies we have shown that IL-1b treatment
leads to the phosphorylation of Runx2 and co-treatment
with a p38 inhibitor blocks this phosphorylation, suggesting
Runx2 as one of the potential downstream targets of p38
action.
In summary, these studies demonstrate the differential in-
hibition of cytokine-induced MMP-1 and -13 expression by
p38 kinase inhibitors in human chondrosarcoma cells while
having weaker inhibitory effects on MMP-1 expression. In-
hibitors of the p38 pathway have been shown to reduce car-
tilage damage in the rat iodoacetate model of OA42. It would
be interesting to test whether treatment of animals and hu-
mans with p38 inhibitors would avoid inducing the MSS
phenotype at doses that result in cartilage protection and
thereby provide a higher safety margin when compared to
the MMP inhibitors previously tested in the clinic. Our
757Osteoarthritis and Cartilage Vol. 14, No. 8studies also suggest the involvement of Runx2, at least in
part, in mediating the effects of p38 on MMP-13 expression.
Inhibition of Runx2 is likely to provide a therapeutic beneﬁt
for OA via the inhibition of MMP-13 expression.
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